Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study
Kimberly K. Leslie, Virginia L. Filiaci, Adrianne Mallen, Kristina W. Thiel, Eric J. Devor, Katherine Moxley, Debra L. Richardson, David G. Mutch, Angeles Alvarez Secord, Krishnansu S. Tewari, Megan McDonald, Cara Mathews, Casey Cosgrove, Summer Dewdney, Yovanni Casablanca, Amanda Jackson, Peter G. Rose, XunClare Zhou, Michael McHale, Heather A. Lankes, Douglas A. Levine, Carol Aghajanian
Topics & Concepts
BevacizumabMedicineOncologyInternal medicineEndometrial cancerGynecologic oncologyTemsirolimusChemotherapyProgression-free survivalTargeted therapyEverolimusCancerPI3K/AKT/mTOR pathwayBiochemistryDiscovery and development of mTOR inhibitorsChemistryApoptosisEndometrial and Cervical Cancer TreatmentsCancer-related Molecular PathwaysAngiogenesis and VEGF in Cancer